Trials / Terminated
TerminatedNCT03675126
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Sarepta Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of SRP-5051 (vesleteplirsen) in participants with Duchenne muscular dystrophy (DMD) who participated in studies of SRP-5051.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SRP-5051 | SRP-5051 administered as an IV infusion. |
Timeline
- Start date
- 2018-12-19
- Primary completion
- 2021-08-25
- Completion
- 2021-08-25
- First posted
- 2018-09-18
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
8 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03675126. Inclusion in this directory is not an endorsement.